"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
| Descriptor ID |
D001559
|
| MeSH Number(s) |
D02.455.426.559.389.115
|
| Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 21 | 19 | 40 |
| 2018 | 34 | 14 | 48 |
| 2019 | 13 | 3 | 16 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Digital Ischemia Induced by Fesoterodine. J Clin Rheumatol. 2021 Sep 01; 27(6):e212-e213.
-
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 09; 9(9):586-594.
-
Dapagliflozin in patients with COVID-19: truth or dare. Lancet Diabetes Endocrinol. 2021 09; 9(9):550-551.
-
Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. J Cardiovasc Pharmacol. 2021 07 01; 78(1):e12-e19.
-
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. Circ Heart Fail. 2021 03; 14(3):e007048.
-
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes Obes Metab. 2021 04; 23(4):886-896.
-
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Curr Atheroscler Rep. 2020 10 03; 22(12):72.
-
Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic. J Coll Physicians Surg Pak. 2020 10; 30(10):110-111.
-
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jul 31; 21(1):690.
-
Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr. 2020 Jul - Aug; 14(4):405-406.